Last $1.67 USD
Change Today -0.0184 / -1.09%
Volume 9.4K
CASI On Other Exchanges
As of 8:10 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

casi pharmaceuticals inc (CASI) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/14 - $2.09
52 Week Low
12/18/14 - $1.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

casi pharmaceuticals inc (CASI) Related Businessweek News

No Related Businessweek News Found

casi pharmaceuticals inc (CASI) Details

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company’s lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

15 Employees
Last Reported Date: 03/21/14
Founded in 1991

casi pharmaceuticals inc (CASI) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $285.2K
Principal Accounting Officer and Vice-Preside...
Total Annual Compensation: $175.1K
Chief Operating Officer, General Counsel and ...
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

casi pharmaceuticals inc (CASI) Key Developments

CASI Pharmaceuticals, Inc. Seeks Acquisition

KEN REN, Chief Executive Officer of CASI Pharmaceuticals, Inc. (Nasdaq:CASI) states, "In 2015, we will further strengthen our management team by adding additional key talent for clinical and commercial development. We will also continue to acquire additional oncology drug candidates to further expand our product pipeline."

CASI Pharmaceuticals, Inc. - Special Call

To discuss and provide a business update and discuss plans for the coming year

CASI Pharmaceuticals, Inc. Elects Ken K. Ren as a Director

On December 3, 2014, the Board of Directors of CASI Pharmaceuticals, Inc. elected Ken K. Ren as a director of the Company, effective immediately. Dr. Ren joined CASI Pharmaceuticals in April 2012 as interim Chief Executive Officer, and after successful completion of the one-year interim period, was appointed Chief Executive Officer in April 2013. Prior to joining CASI Pharmaceuticals from 2005-2012, Dr. Ren was the president of Accelovance (China).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CASI:US $1.67 USD -0.0184

CASI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $222.36 USD -3.39
Novartis AG SFr.89.40 CHF +0.70
Regeneron Pharmaceuticals Inc $408.00 USD -7.74
View Industry Companies

Industry Analysis


Industry Average

Valuation CASI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 65.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CASI PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at